Stapokibart and Tislelizumab for advanced lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new combination of two drugs (Stapokibart and Tislelizumab) for people with non-small cell lung cancer that has not responded to initial treatment and has no specific gene mutations. The goal is to see if this combo can help when other options have been exhausted.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have non-small cell lung cancer that does not have a driver gene mutation (like EGFR).
- Your cancer got worse after first-line standard treatment, and you cannot get other chemotherapy.
- You have at least one measurable tumor that can be seen on scans.
- You are able to do daily activities without help (ECOG 0 or 1).
- Your organs (kidneys, liver, bone marrow, heart) are working well, based on lab tests.
- You have not had certain prior treatments (like anti-IL-4Rα drugs or severe side effects from immunotherapy).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs (tislelizumab and anlotinib) for people with advanced lung cancer whose first immunotherapy treatment stopped working. The goal is to see if this new combination can help when the first treatment stopped being effective.
This study tests a combination of three treatments—an immunotherapy drug called tislelizumab, chemotherapy, and a procedure called BACE—for advanced lung cancer that cannot be surgically removed. The goal is to see if this combination can shrink tumors and help patients live longer.
This trial tests if adding the immunotherapy drug Tislelizumab to standard chemotherapy can shrink stage III non-small cell lung cancer that cannot be surgically removed at first. The goal is to see if this combination makes the cancer small enough for surgery.
This trial tests whether a new drug combination (SYS6010 plus enlonstobart) works better than standard immunotherapy with chemotherapy for patients with advanced non-small cell lung cancer. You may qualify if you have not received prior cancer treatment and have a specific marker (PD-L1) on your tumor.
This trial tests a drug called Tislelizumab (an immunotherapy) combined with chemotherapy for people with advanced NSCLC who have already been helped by a different immunotherapy. It's a second-line option for those who did well on their first immunotherapy but now need another treatment.
This study tests a new drug called stapokibart combined with immune checkpoint inhibitors, which are treatments that help your immune system fight cancer. It is for people with lymphoma that has come back or not responded to previous treatments.
Hear when a new Lung Cancer (NSCLC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.